The next focusIR Investor Webinar takes places on 14th May with guest speakers from Blue Whale Growth Fund, Taseko Mines, Kavango Resources and CQS Natural Resources fund. Please register here.
The problem is that their appalling communication ( and i mean by that the very poor quality RNS’s that they have issued this year ) have totally undermined credibility and, therefore, the share price.
So let’s say you are right and this pharma takes a £10m equity stake. With a market cap of £18m that’s a dilutionary disaster for shareholders.
I really fear these guys are showing the sort of arrogance we have witnessed at Angle for anyone who has followed that disaster.
Sadly not.
I must admit i have called this wrong. I thought Rudd was still a serious person and would have a serious team. Seems i made a mistake.
The hopeless RNS’s earlier this year were a clear sign these guys were well out of their depth.
Ok thanks EC.
So that says - full approval in the US for Breast cancer. No restrictions. Good.
And it says use for all other cancers restricted to drug trials.
Is that correct?
Isn’t that what TG2D has been saying or am i missing something?
TG2D - now you mention it i remember that. Word soup. Absolutely he was vague. I wonder why.
Miavoce - the question is what specific statements can you source direct from Angle that supports your view? I think you might struggle.
I absolutely don’t know the answer to this question of what precisely Parsortix can be used for ATM - but given the history of this company that certainly raises a question or two.
Hi Miavoce
Commercially - i agree. Shareholders do not need to understand in order for Newland to close some deals.
But it’s a point of basic communication. Why not make it totally clear to your shareholders? I mean if it is as you think, allowing this confusion is just id1otic when you would think you need a strong share price for an equity issue in due course.
And the fact that Newland hasn’t closed any significant deals ( yes i do know about the $250k Eisai ) raises questions doesn’t it ?
The fact that this confusion exits is symptomatic of the failures of communication of this company.
It should be crystal clear from Angle’s communications exactly what can and cannot be done today and what that means commercially. It should be very simple to spell this out.
I admit to being confused on this point.
It’s very basic and very important.
I agree TG2D.
I have seen lists of so-called target markets but few seem to last long enough to be reported on. But I have seen no commercial or strategic plan.
IMO - the plan can be summarised as ‘ somewhere over the rainbow skies are blue’.
Jackbal - agreed on all.
IMO most Board’s would have fired him now for serially raising expectations allied with zero delivery. And he’s burned through £100m if i remember correctly.
But my guess is there is no obvious replacement so this pack of cards stands or falls with him. So i think i know how this might end…..